Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients

John Romano, Omar T. Sims, Joshua Richman, Yuqi Guo, Tasnia Matin, Mohamed Shoreibah, Vishnu Kommineni, Krishna Venkata, Omar Massoud

JGH Open · 2018 · 15 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Background and Aims The aims of this study were to examine changes in the proportion of decompensated hepatitis C virus (HCV) cirrhosis patients with ascites, hepatic encephalopathy, and variceal bleeding at pretreatment compared to 3 and 12 months post‐sustained virological response (SVR) and to compare pretreatment and post‐SVR model of end‐stage liver disease and Child‐Pugh scores and alpha‐fetoprotein levels. Methods Electronic medical records of 64 decompensated HCV cirrhosis patients who received direct‐acting antivirals were reviewed. The McNemar–Bowker test and the Wilcoxon‐Signed Rank test were used to compare patient outcomes. Results Ascites was resolved in 29% of patients 3 months post‐SVR (65% vs 36%, P < 0.01) and in 35% of patients 12 months post‐SVR (65% vs 30%, P = 0.07). Hepatic encephalopathy was resolved in 54% of patients 3 months post‐SVR (70% vs 16%, P < 0.01) and in 48% of patients 12 months post‐SVR (70% vs 22% P = 0.03). Variceal bleeding was absent in 32% of patients 3 months post‐SVR (35% vs 3%, P < 0.01) and in 27% of patients 12 months post‐SVR (35% vs 8%, P < 0.01). Alpha‐fetoprotein levels were significantly reduced post‐SVR, but model of end‐stage liver disease and Child‐Pugh scores were not. Conclusions Decompensated HCV cirrhosis patients who achieved SVR with direct‐acting antiviral treatment had significant reductions in manifestations of hepatic decompensation sustainable up to 1 year post‐SVR.

References

23